\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ revealed\\ bilateral\\ nasal\\ polyps\\.\ \(0\)\
\-\ patient\\ underwent\\ bifrontal\\ craniotomy\\ and\\ lateral\\ rhinotomy\\.\ \(0\)\
\-\ mri\\ of\\ the\\ brain\\ pre\\ and\\ post\\ gadolinium\\ demonstrates\\ a\\ t1\\ dark\\,\\ t2\\ intermediate\\ to\\ hyperintense\\ lesion\\ emanating\\ from\\ the\\ anterior\\ cranial\\ fossa\\ into\\ the\\ left\\ nasal\\ region\\ with\\ moderate\\,\\ homogeneous\\ contrast\\ enhancement\\.\\ \\ there\\ is\\ also\\ a\\ t1\\ dark\\,\\ t2\\ bright\\ signal\\ present\\ in\\ the\\ left\\ maxillary\\ sinus\\,\\ sphenoid\\ sinus\\,\\ and\\ the\\ left\\ frontal\\ ethmoid\\ recess\\,\\ which\\ demonstrates\\ a\\ peripheral\\ rim\\ of\\ enhancement\\.\ \(0\)\
\-\ olfactory\\ neuroblastoma\ \(0\)\
\-\ neoplastic\ \(113\)\
\-\ olfactory\\ neuroblastoma\ \(0\)\
\-\ squamous\\ cell\\ carcinoma\ \(52\)\
\-\ extramedullary\\ plasmacytoma\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ lymphoma\ \(373\)\
\-\ melanoma\ \(92\)\
\-\ rhabdomyosarcoma\ \(41\)\
\-\ non\\-neoplastic\ \(2\)\
\-\ frontoethmoid\\ mucocele\ \(0\)\
\-\ invasive\\ aspergilloma\ \(0\)\
\-\ nasal\\ polyposis\ \(2\)\
\-\ 50\\ year\\-old\\,\\ white\\ male\\ with\\ 12\\ month\\ history\\ of\\ left\\ nasal\\ obstruction\\ and\\ recurrent\\ epistaxis\\.\ \(1\)\
\-\ ct\\ and\\ mri\\ are\\ valuable\\ tools\\ in\\ evaluating\\ anterior\\ skull\\ base\\ tumors\\.\\ \\ while\\ the\\ appearances\\ of\\ these\\ tumors\\ tend\\ to\\ be\\ nonspecific\\,\\ there\\ are\\ certain\\ characteristics\\ that\\ may\\ help\\ in\\ narrowing\\ the\\ differential\\ such\\ as\\.\\.\\.\ \(0\)\
\-\ broad\\-based\\ interface\\ with\\ the\\ anterior\\ cranial\\ fossa\ \(0\)\
\-\ \\ \\ \\ \\-squamous\\ cell\\ carcinoma\\,\\ esthesioneuroblastoma\\,meningioma\ \(1\)\
\-\ marginal\\ cysts\ \(0\)\
\-\ \\ \\ \\ \\-esthesioneuroblastoma\ \(1\)\
\-\ diffuse\\,\\ marked\\ enhancement\ \(0\)\
\-\ \\ \\ \\ \\-meningioma\\,\\ hemangiopericytoma\\,\\ plasmacytoma\ \(1\)\
\-\ tumoral\\ calcifications\ \(1\)\
\-\ \\ \\ \\ \\-chondrosarcoma\\,\\ teratoma\\,\\ meningioma\\,\\ esthesioneuroblastoma\ \(1\)\
\-\ linear\\ \\"dural\\ tail\\"\\ of\\ enhancement\ \(0\)\
\-\ \\ \\ \\ \\-meningiomas\\,\\ neuromas\\,\\ mets\\,\\ adenocystic\\ carcinomas\ \(1\)\
\-\ sclerotic\\ or\\ hyperostotic\\ bone\\ reaction\ \(0\)\
\-\ \\ \\ \\ \\-osteoblastic\\ mets\\,\\ meningiomas\\,\\ fibro\\-osseous\\ lesions\\,\ \(1\)\
\-\ \\ \\ \\ \\ pervious\\ radiotherapy\ \(1\)\
\-\ bone\\ destruction\ \(12\)\
\-\ \\ \\ \\ \\-scc\\,\\ sarcomas\\,\\ mets\\,\\ lymphoma\ \(0\)\
\-\ bony\\ remodeling\ \(8\)\
\-\ \\ \\ \\ \\-neuromas\\,\\ meningiomas\\,\\ plasmacytomas\\,\\ sarcomas\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ esthesioneuroblastoma\\:\\ 0\\.06630507137474738\ \(0\)\
\-\ \\-squamous\\:\\ 0\\.06299515212488481\ \(0\)\
\-\ \\-meningioma\\:\\ 0\\.06064672704364578\ \(0\)\
\-\ mets\\:\\ 0\\.060290181132929034\ \(0\)\
\-\ nasal\\:\\ 0\\.05180266463627664\ \(0\)\
\-\ sarcomas\\:\\ 0\\.051025053604122135\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.047508458370714345\ \(0\)\
\-\ meningiomas\\:\\ 0\\.046730416086597414\ \(0\)\
\-\ dark\\:\\ 0\\.03814190773530585\ \(0\)\
\-\ enhancement\\:\\ 0\\.03739573495711079\ \(0\)\
\-\ \\-olfactory\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-melanoma\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-frontoethmoid\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-invasive\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-esthesioneuroblastoma\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-chondrosarcoma\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-meningiomas\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-osteoblastic\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ pervious\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-scc\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ \\-neuromas\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ plasmacytomas\\:\\ 0\\.03598170785292449\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.0348752950342571\ \(0\)\
\-\ \\-rhabdomyosarcoma\\:\\ 0\\.03315253568737369\ \(0\)\
\-\ hyperostotic\\:\\ 0\\.03315253568737369\ \(0\)\
\-\ rhinotomy\\:\\ 0\\.031497576062442405\ \(0\)\
\-\ \\-extramedullary\\:\\ 0\\.031497576062442405\ \(0\)\
\-\ \\-nasal\\:\\ 0\\.031497576062442405\ \(0\)\
\-\ adenocystic\\:\\ 0\\.031497576062442405\ \(0\)\
\-\ \\,\\:\\ 0\\.0309382932019757\ \(0\)\
\-\ cranial\\:\\ 0\\.030331853029733062\ \(0\)\
\-\ aspergilloma\\:\\ 0\\.03032336352182289\ \(0\)\
\-\ tools\\:\\ 0\\.03032336352182289\ \(0\)\
\-\ neuromas\\:\\ 0\\.03032336352182289\ \(0\)\
\-\ \\-mri\\:\\ 0\\.02941257351645877\ \(0\)\
\-\ fibro\\-osseous\\:\\ 0\\.02941257351645877\ \(0\)\
\-\ non\\-neoplastic\\:\\ 0\\.028668403896891605\ \(0\)\
\-\ fossa\\:\\ 0\\.028431017393478607\ \(0\)\
\-\ emanating\\:\\ 0\\.027013444271960323\ \(0\)\
\-\ anterior\\:\\ 0\\.026948483556278418\ \(0\)\
\-\ meningioma\\:\\ 0\\.026825219073102657\ \(0\)\
\-\ polyposis\\:\\ 0\\.026583401350907972\ \(0\)\
\-\ tumors\\:\\ 0\\.026201766185065315\ \(0\)\
\-\ bifrontal\\:\\ 0\\.026194380208849503\ \(0\)\
\-\ valuable\\:\\ 0\\.026194380208849503\ \(0\)\
\-\ tumoral\\:\\ 0\\.025839231731340808\ \(0\)\
\-\ olfactory\\:\\ 0\\.025512526802061068\ \(0\)\
\-\ \\-lymphoma\\:\\ 0\\.025512526802061068\ \(0\)\
\-\ appearances\\:\\ 0\\.025512526802061068\ \(0\)\
\-\ sinus\\:\\ 0\\.025511501792999495\ \(0\)\
\-\ epistaxis\\:\\ 0\\.025210045283066286\ \(0\)\
\-\ broad\\-based\\:\\ 0\\.023754229185357172\ \(0\)\
\-\ recess\\:\\ 0\\.023555085658135\ \(0\)\
\-\ pre\\:\\ 0\\.02301005956579001\ \(0\)\
\-\ marginal\\:\\ 0\\.022843439179993052\ \(0\)\
\-\ certain\\:\\ 0\\.02238087311751549\ \(0\)\
\-\ carcinomas\\:\\ 0\\.02238087311751549\ \(0\)\
\-\ mucocele\\:\\ 0\\.02223764324073479\ \(0\)\
\-\ t1\\:\\ 0\\.02211016764264689\ \(0\)\
\-\ \\.\\.\\.\\:\\ 0\\.02209926956042589\ \(0\)\
\-\ remodeling\\:\\ 0\\.02209926956042589\ \(0\)\
\-\ interface\\:\\ 0\\.02158839958918505\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.02124326739315214\ \(0\)\
\-\ polyps\\:\\ 0\\.021134417405061685\ \(0\)\
\-\ craniotomy\\:\\ 0\\.020925057019806376\ \(0\)\
\-\ hemangiopericytoma\\:\\ 0\\.020824270845968124\ \(0\)\
\-\ ethmoid\\:\\ 0\\.02035460011215267\ \(0\)\
\-\ intermediate\\:\\ 0\\.020096727044309683\ \(0\)\
\-\ tend\\:\\ 0\\.019776434736385212\ \(0\)\
\-\ carcinoma\\:\\ 0\\.019770838122578505\ \(0\)\
\-\ t2\\:\\ 0\\.01974358178571716\ \(0\)\
\-\ sphenoid\\:\\ 0\\.019408471075183998\ \(0\)\
\-\ evaluating\\:\\ 0\\.019408471075183998\ \(0\)\
\-\ tail\\:\\ 0\\.019202630856298725\ \(0\)\
\-\ maxillary\\:\\ 0\\.019070953867652923\ \(0\)\
\-\ cell\\:\\ 0\\.018842781319032543\ \(0\)\
\-\ nonspecific\\:\\ 0\\.01794562373946898\ \(0\)\
\-\ neoplastic\\:\\ 0\\.017848437418270132\ \(0\)\
\-\ bright\\:\\ 0\\.01743764751712855\ \(0\)\
\-\ help\\:\\ 0\\.017394455234146768\ \(0\)\
\-\ characteristics\\:\\ 0\\.017351715234688418\ \(0\)\
\-\ bone\\:\\ 0\\.017334160664978532\ \(0\)\
\-\ destruction\\:\\ 0\\.017226116627885344\ \(0\)\
\-\ dural\\:\\ 0\\.016908937100018742\ \(0\)\
\-\ gadolinium\\:\\ 0\\.016544263221096908\ \(0\)\
\-\ homogeneous\\:\\ 0\\.0165095257122483\ \(0\)\
\-\ teratoma\\:\\ 0\\.016307089217801884\ \(0\)\
\-\ reaction\\:\\ 0\\.0158409979217788\ \(0\)\
\-\ sclerotic\\:\\ 0\\.015612595253827601\ \(0\)\
\-\ left\\:\\ 0\\.015609881947312896\ \(0\)\
\-\ demonstrates\\:\\ 0\\.01523772409512805\ \(0\)\
\-\ skull\\:\\ 0\\.014854566087317018\ \(0\)\
\-\ linear\\:\\ 0\\.014785965604393013\ \(0\)\
\-\ rim\\:\\ 0\\.014763352623268054\ \(0\)\
\-\ recurrent\\:\\ 0\\.014718499065816643\ \(0\)\
\-\ hyperintense\\:\\ 0\\.014480245979196614\ \(0\)\
\-\ 12\\:\\ 0\\.014275095633152171\ \(0\)\
\-\ narrowing\\:\\ 0\\.013985496710816317\ \(0\)\
\-\ bony\\:\\ 0\\.013948390703872432\ \(0\)\
\-\ moderate\\:\\ 0\\.01371509105554611\ \(0\)\
\-\ base\\:\\ 0\\.013663095031964764\ \(0\)\
\-\ cysts\\:\\ 0\\.013663095031964764\ \(0\)\
\-\ marked\\:\\ 0\\.013611753063773498\ \(0\)\
\-\ 50\\:\\ 0\\.013269379659770632\ \(0\)\
\-\ calcifications\\:\\ 0\\.012968015325031643\ \(0\)\
\-\ year\\-old\\:\\ 0\\.012811284170196804\ \(0\)\
\-\ peripheral\\:\\ 0\\.012620136008220888\ \(0\)\
\-\ obstruction\\:\\ 0\\.01229959203505892\ \(0\)\
\-\ underwent\\:\\ 0\\.01196814708358457\ \(0\)\
\-\ white\\:\\ 0\\.011567772296783747\ \(0\)\
\-\ revealed\\:\\ 0\\.01119377097904528\ \(0\)\
\-\ differential\\:\\ 0\\.011073305425930326\ \(0\)\
\-\ post\\:\\ 0\\.010983000134988955\ \(0\)\
\-\ while\\:\\ 0\\.010974078530009444\ \(0\)\
\-\ frontal\\:\\ 0\\.010956293610136154\ \(0\)\
\-\ such\\:\\ 0\\.010903399142207561\ \(0\)\
\-\ diffuse\\:\\ 0\\.010559213960715571\ \(0\)\
\-\ brain\\:\\ 0\\.010495312340011274\ \(0\)\
\-\ month\\:\\ 0\\.010463732819594325\ \(0\)\
\-\ there\\:\\ 0\\.010381351481346847\ \(0\)\
\-\ lymphoma\\:\\ 0\\.009968157691385657\ \(0\)\
\-\ region\\:\\ 0\\.009851433580568624\ \(0\)\
\-\ are\\:\\ 0\\.009509174469629404\ \(0\)\
\-\ lesions\\:\\ 0\\.009336981658546727\ \(0\)\
\-\ signal\\:\\ 0\\.009196221756215425\ \(0\)\
\-\ these\\:\\ 0\\.009076917110032001\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.00857197974543599\ \(0\)\
\-\ physical\\:\\ 0\\.008557164365637708\ \(0\)\
\-\ bilateral\\:\\ 0\\.008464562160467119\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.00840714082441732\ \(0\)\
\-\ into\\:\\ 0\\.008299291297794723\ \(0\)\
\-\ mri\\:\\ 0\\.008013370836386204\ \(0\)\
\-\ present\\:\\ 0\\.007877586750741555\ \(0\)\
\-\ contrast\\:\\ 0\\.007807247701256757\ \(0\)\
\-\ exam\\:\\ 0\\.007662179346732809\ \(0\)\
\-\ may\\:\\ 0\\.007650319873053567\ \(0\)\
\-\ lateral\\:\\ 0\\.00753742059438592\ \(0\)\
\-\ lesion\\:\\ 0\\.0071043070448998154\ \(0\)\
\-\ also\\:\\ 0\\.006875998341510823\ \(0\)\
\-\ which\\:\\ 0\\.006510794233643057\ \(0\)\
\-\ male\\:\\ 0\\.006306961379132544\ \(0\)\
\-\ that\\:\\ 0\\.0060244111369747895\ \(0\)\
\-\ be\\:\\ 0\\.005378598870791548\ \(0\)\
\-\ as\\:\\ 0\\.00527582655466991\ \(0\)\
\-\ from\\:\\ 0\\.005169125359813112\ \(0\)\
\-\ in\\:\\ 0\\.00515996608335006\ \(0\)\
\-\ ct\\:\\ 0\\.004878790422008339\ \(0\)\
\-\ a\\:\\ 0\\.00485632410390124\ \(0\)\
\-\ history\\:\\ 0\\.00481720219472279\ \(0\)\
\-\ the\\:\\ 0\\.004514262357669414\ \(0\)\
\-\ or\\:\\ 0\\.004087847954953909\ \(0\)\
\-\ and\\:\\ 0\\.0036736531782085398\ \(0\)\
\-\ patient\\:\\ 0\\.003496293595577094\ \(0\)\
\-\ to\\:\\ 0\\.0034862702730039698\ \(0\)\
\-\ of\\:\\ 0\\.0023776285877140494\ \(0\)\
\-\ is\\:\\ 0\\.002295064401570309\ \(0\)\
\-\ with\\:\\ 0\\.0014327041970190579\ \(0\)\
\-\ \\.\\:\\ 0\\.000869376394220725\ \(0\)\
